Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
14/04/2026 21:32
April 14 (Reuters) - Cabaletta Bio Inc CABA.O: FIRST PATIENTS DOSED WITH CABALETTA BIO’S RESE-CEL MANUFACTURED ON CELLARES' AUTOMATED CELL SHUTTLE™ PLATFORM Source text: ID:nBw8B8Lnda Further company coverage: CABA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsBrief: Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Cabaletta Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Cabaletta Bio Q2 net loss widens as R&D costs rise
Cabaletta Bio, Inc. expected to post a loss of 37 cents a share - Earnings Preview
Cabaletta Bio Inc expected to post a loss of 37 cents a share - Earnings Preview